Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial tags : Europe save search
Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
Published: 2024-04-08 (Crawled : 11:00) - biospace.com/
OCS | $11.81 -0.76% -0.76% 57K
|
n/a
|
| O: 0.36%
H: 0.18%
C: -2.76%
ocs-01 positive treatment for meeting trial results
ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses
Published: 2024-03-04 (Crawled : 21:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -1.09%
H: 0.61%
C: -1.56%
trial
SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa
Published: 2024-01-24 (Crawled : 00:00) - biospace.com/
NTLA | $21.3 -0.93% -0.94% 1.1M
|
Health Technology
|
| O: 1.28%
H: 1.0%
C: -4.06%
spvn06 trial
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024
Published: 2024-01-24 (Crawled : 10:00) - biospace.com/
ABVX | $14.84 -0.27% -0.27% 6.8K
|
n/a
|
| O: -1.76%
H: 3.24%
C: 1.36%
active review trial
Enthera Pharmaceuticals Appoints Lisa M. Olson as CEO and Announces Clinical Trial Progress with Ent001
Published: 2024-01-23 (Crawled : 12:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.46%
H: 0.74%
C: -0.04%
ABT | News | $105.27 -0.6% -0.15% 7.3M
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: 0.0%
ceo pharmaceuticals trial
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma
Published: 2024-01-09 (Crawled : 13:30) - biospace.com/
NVCR | $12.04 -0.08% -0.08% 1.4M
|
Health Technology
|
| O: 1.25%
H: 4.12%
C: -2.06%
trial glioblastoma
INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer’s Disease in Europe
Published: 2023-11-15 (Crawled : 14:00) - globenewswire.com
INMB | $8.79 4.27% 4.1% 98K
|
Health Technology
|
| O: 2.48%
H: 7.55%
C: 1.42%
europe disease alzheimer’s expansion trial
Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program
Published: 2023-10-18 (Crawled : 11:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M
|
Health Technology
|
| O: -0.01%
H: 0.3%
C: -0.99%
europe sciences hiv program trial
AviadoBio Announces Initiation of Phase 1/2 Clinical Trial, ASPIRE-FTD, Evaluating AVB-101 in People with Frontotemporal Dementia with GRN Mutations
Published: 2023-10-10 (Crawled : 12:00) - biospace.com/
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 0.67%
H: 0.56%
C: -0.01%
avb-101 dementia
ENHERTU® Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2 Mutant Advanced Lung Cancer in DESTINY-Lung02 Phase 2 Trial
Published: 2023-09-11 (Crawled : 11:00) - biospace.com/
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: -3.31%
H: 1.02%
C: 0.97%
enhertu lung her2 cancer tumor trial
First Patient Enrolled in Phase 1/2 “ELUCIDATE” Trial Assessing GTAEXS617 in Advanced Solid Tumours
Published: 2023-07-10 (Crawled : 12:20) - biospace.com/
EXAI | $4.35 0.69% 0.69% 330K
|
|
| O: 0.88%
H: 11.11%
C: 6.03%
taexs617 trial
Long-Term Data From the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection With Methotrexate Published in ACR Open Rheumatology
Published: 2023-07-06 (Crawled : 15:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.03%
H: 0.0%
C: -0.29%
krystexxa trial injection
Elios Vision Achieves Pipeline Milestone with Enrollment Completion in U.S. Pivotal Trial, Expands U.S. Pre-launch Team, and Continues to Generate Commercial Uptake in Europe
Published: 2023-06-28 (Crawled : 14:00) - prnewswire.com
FNCTF | News | $11.0354 -20.84% 34K
|
Communications
| Email alert
Add to watchlist
europe pipeline commercial milestone
UPLIZNA® (inebilizumab-cdon) Pivotal Trial Publication Integrating MRI and Biomarker Evaluation Shows Accuracy and Uniformity of Attack Diagnoses for Neuromyelitis Optica Spectrum Disorder (NMOSD)
Published: 2023-06-12 (Crawled : 16:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.73%
H: 0.0%
C: -0.15%
uplizna biomarker publication trial
LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Published: 2023-06-06 (Crawled : 15:00) - biospace.com/
NVCR | $12.04 -0.08% -0.08% 1.4M
|
Health Technology
|
| O: -9.53%
H: 0.68%
C: -37.04%
lung cancer cell extension trial
ANeuroTech receives IND approval from the FDA for pivotal Phase IIIB trial of adjunctive anti-depression drug, ANT-01
Published: 2023-06-05 (Crawled : 23:00) - biospace.com/
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -0.14%
H: 1.21%
C: 1.0%
ant-01 fda approval trial
Datopotamab Deruxtecan Combinations Showed Encouraging Tumor Responses in Patients with Advanced Non-Small Cell Lung Cancer in TROPION-Lung02 Phase 1b trial
Published: 2023-06-05 (Crawled : 17:00) - biospace.com/
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: 0.39%
H: 0.78%
C: 0.45%
lung cancer cell tumor trial
New Analyses of the MIRROR Randomized Controlled Trial in Uncontrolled Gout Presented at the 2023 EULAR European Congress of Rheumatology
Published: 2023-05-31 (Crawled : 17:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.1%
H: 1.32%
C: 0.58%
trial
Presentations at the 2023 EULAR European Congress of Rheumatology Highlight New Results from Phase 2 Trial Evaluating Dazodalibep in Sjögren’s Syndrome
Published: 2023-05-31 (Crawled : 12:20) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: 0.1%
H: 1.32%
C: 0.58%
trial results
ADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress
Published: 2023-05-11 (Crawled : 19:00) - biospace.com/
ADCT | $4.76 -4.03% 0.0% 280K
|
Health Technology
|
| O: 0.83%
H: 7.02%
C: -0.41%
association trial therapeutics results
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.